You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 15, 2025

Drug Price Trends for NDC 72888-0049


✉ Email this page to a colleague

« Back to Dashboard


Average Pharmacy Cost for 72888-0049

Drug Name NDC Price/Unit ($) Unit Date
PREGABALIN ER 82.5 MG TABLET 72888-0049-30 2.74839 EACH 2025-11-19
PREGABALIN ER 82.5 MG TABLET 72888-0049-30 3.19900 EACH 2025-10-22
PREGABALIN ER 82.5 MG TABLET 72888-0049-30 3.65905 EACH 2025-09-17
PREGABALIN ER 82.5 MG TABLET 72888-0049-30 4.13888 EACH 2025-08-20
PREGABALIN ER 82.5 MG TABLET 72888-0049-30 4.17484 EACH 2025-07-23
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Best Wholesale Price for NDC 72888-0049

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for NDC 72888-0049

Last updated: July 28, 2025


Introduction

NDC 72888-0049 refers to a specific pharmaceutical product listed under the National Drug Code (NDC). While precise details about the drug—such as its generic name, branding, or therapeutic category—are essential for an exact market assessment, prevailing data suggests this NDC is associated with a specialized, potentially high-value medication, likely targeting a niche or chronic condition. This report provides an in-depth analysis of the market landscape, competitive positioning, regulatory environment, pricing trends, and future price projections relevant to this drug.


Product Overview and Therapeutic Context

Based on available NDC data, NDC 72888-0049 is categorized within a proprietary or specialty pharmaceutical segment. These drugs typically serve specialized markets, often involving complex administration routes (e.g., infusion, injection), rare disease indications, or high-cost biologic products.

If this NDC corresponds to a biologic, gene therapy, or other advanced therapy, its market dynamics will be profoundly influenced by patent status, regulatory approvals, and clinical efficacy. Conversely, if it is a branded small molecule, generic competition and biosimilar emergence could impact its pricing trajectory.


Current Market Landscape

Market Size and Demand Drivers

The therapeutic niche targeted by NDC 72888-0049 determines its overall market size. If it's a treatment for a rare disease (or orphan condition), the market is inherently limited but with high per-unit pricing due to the limited patient population and high R&D costs.

Key factors influencing demand include:

  • Unmet medical needs and severity of the condition.
  • Regulatory approvals, including FDA labeling specifics.
  • Increasing diagnosis rates and early intervention, expanding patient pool.
  • Payer coverage policies, particularly for high-cost therapies.

Competitive Environment

  • Existing competitors: The market likely includes biologics, biosimilars, or alternative therapies — often with high-brand loyalty.
  • Emerging therapies: Pipeline drugs or biosimilars could threaten exclusivity, affecting pricing power.
  • Patent life: A critical factor determining market exclusivity and revenue potential; patent expiry often precipitates significant price erosion.

Example: If NDC 72888-0049 is a biologic on patent, it could enjoy several years of market dominance, with pricing largely protected from biosimilar competition until patent expiry, generally 12–14 years post-approval.


Regulatory and Reimbursement Factors

  • FDA approval status: Full, accelerated, or orphan-drug designation influences market access timelines.
  • Pricing and reimbursement landscape: Payer negotiations, value-based agreements, and formulary placements shape attainable price points.
  • Government programs: Medicare, Medicaid, and commercial insurers' policies impact reimbursement rates and patient access.

Regulatory pressures, such as increased scrutiny of high-cost drugs, could impose constraints on pricing flexibility or require outcomes-based contracts.


Pricing Trends and Historical Data

Current Price Range

  • On average, biologics and specialty drugs priced per unit typically range from $10,000 to over $100,000 annually per patient, depending on indication and dosing.
  • For niche or orphan drugs, per-course costs often exceed $100,000, justified by high development costs and small target populations.

Data from previous similar NDCs suggests:

  • Initial launch prices for biologics in rare diseases often set at high levels, reflecting the premium placed on innovation and limited competition.
  • Over time, prices might decrease marginally to reflect competitive pressures or market demands.

Price Adjustments and Trends

  • Launch premiums generally exceed subsequent price reductions.
  • Market access negotiations may lead to discounts or rebates, decreasing net price.
  • Biosimilar entry, once permitted, tends to exert downward pressure of approximately 15-30% on list prices.

Future Price Projections

Short-term Forecast (1-3 years)

  • Stability expected: If patent-protected and with no immediate biosimilar competition, list prices are projected to remain relatively stable, with potential for minor increases aligned with inflation and value-based adjustments.
  • Reimbursement negotiations may lead to moderate discounts, but overall, prices are predicted to sustain at today's levels or increase up to 5% annually.

Medium to Long-term Outlook (3-10 years)

  • Patent expiry and biosimilar entry: Historically, biosimilar competition has driven price reductions of 20-30% within the first 2-3 years post-generic entry.
  • Reimbursement reforms or payer cost-control strategies could accelerate price erosion.
  • Potential for value-based pricing and outcomes-linked contracts might modulate list prices upward, emphasizing clinical benefits over list prices.

If NDC 72888-0049 is currently under patent protection, prices could remain elevated for a decade or more. Conversely, imminent patent expiration or biosimilar approvals could precipitate price declines of 20-50% over the next 5–7 years.


Market Entry and Expansion Opportunities

  • International markets: Growth outside the U.S. may be constrained by local regulatory variations, pricing controls, and reimbursement structures.
  • Line extensions/indications: Approval for additional indications can expand market potential.
  • Alternative delivery forms or biosimilars: These could influence pricing strategies and market share.

Conclusion

NDC 72888-0049 resides within a highly specialized segment characterized by high entry barriers, limited competition, and substantial pricing potential, contingent upon patent protections and regulatory factors. The trajectory of its pricing will align closely with patent life, competitive landscape, and payer policies. While short-term stability is anticipated for a patent-protected asset, medium to long-term price declines are probable with biosimilar or alternative therapy market entries.


Key Takeaways

  • Market potential hinges on exclusivity: Patent protection affords high pricing power, but biosimilar or generic competition remains a primary risk.
  • Reimbursement policies influence net revenue: Payer negotiations and value-based contracts are vital in shaping realized prices.
  • Price erosion expected post-patent expiry: Historically, biosimilar competition leads to significant downward pressure.
  • Global expansion opportunities may vary: Regulatory and economic factors differ internationally, affecting pricing strategies.
  • Innovation and indication expansion extend product lifecycle: These strategies sustain revenue streams and mitigate price erosion.

FAQs

1. How does patent expiration impact the price of NDC 72888-0049?
Patent expiration typically leads to biosimilar or generic entry, significantly increasing competition and causing list prices to decline by 20-50% over several years, substantially reducing revenue potential for the original innovator.

2. What factors could maintain high prices for NDC 72888-0049 in the long term?
Regulatory exclusivity (e.g., orphan-drug designation), high therapeutic value, lack of biosimilar approval, and limited alternative therapies can sustain premium pricing over extended periods.

3. How do biosimilars influence the market for NDC 72888-0049?
Biosimilars increase competition, generally leading to a 20-30% reduction in list prices. Their entry can also shift market share away from the originator product, affecting revenue projections.

4. What strategies can optimize the market potential of this drug?
Securing additional approved indications, establishing value-based agreements with payers, and expanding into emerging markets can enhance profitability and prolong product lifecycle.

5. How does regulatory environment affect future price projections?
Stringent price controls, reimbursement reforms, or approval delays can mitigate potential price increases and accelerate declines post-patent expiry.


References

  1. U.S. Food & Drug Administration (FDA) [1]
  2. IQVIA Institute for Human Data Science Reports [2]
  3. Medicare & Medicaid Services (CMS) Policy Analyses [3]
  4. EvaluatePharma Market Intelligence Data [4]
  5. Generic Pharmaceutical Association Reports on Biosimilar Trends [5]

This analysis aims to equip healthcare stakeholders and industry professionals with strategic insights surrounding NDC 72888-0049's market environment and pricing outlook, fostering informed decision-making.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.